Holen Sie sich die Stockscreener-App
0.723
14.42%
-0.1218
Handel nachbörslich:
.73
0.007
+0.97%
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
Total assets of MIRA Pharmaceuticals, Inc. – HAN:K6S - TradingView
Millions of Cancer Patients and Survivors Live With Persistent Nerve Pain. MIRA Is Advancing Ketamir-2 Into Its First Patient Study - Barchart.com
What's Behind MIRA Pharmaceuticals, Inc.'s (MIRA) Big Moment in Cannabis Stocks? - kalkinemedia.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review - Investing.com
MIRA Advances Ketamir-2 Phase 2a Trial Protocol for CIPN; Market Reflects Cautious Outlook - GuruFocus
MIRA advances Ketamir-2 Phase 2a neuropathy program - TipRanks
MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com India
Maxim Group Initiates MIRA Pharmaceuticals(MIRA.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review - Yahoo Finance
63% of MIRA Pharmaceuticals (MIRA) shares vote to reelect board and back 2026 auditor - Stock Titan
Nearly 300 flights are cancelled due to problems in UK air traffic control system, flight monitor Flightradar24 reports - barchart.com
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
This Under-the-Radar Biopharma Is Moving MIRA-55, a Non-Opioid Pain Drug That Outperformed Morphine Closer to the Clinic - Barchart.com
Mira advances IND-enabling studies of MIRA-55 for pain - BioWorld News
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com South Africa
MIRA-55 toxicology results advance non-opioid pain program - TipRanks
MIRA Pharmaceuticals reports toxicology data for pain drug candidate - Investing.com
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND - GlobeNewswire
MIRA (MIRA) Results Breakdown: The Company Lists Its Latest Available Figures for This Review; Shares Move 4.66% HigherEPS Estimate Trend - dars.gov.et
MIRA (MIRA) Update: Holds Near $0.73 on the Day; Key Range: $0.69 and $0.77 Define the Nearby Reference Levels for the Current SessionSocial Sentiment - dars.gov.et
MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest ReadingSegment Revenue Breakdown - vinanet.vn
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusBanking Earnings Report - vinanet.vn
MIRA Pharmaceuticals (MIRA) Earnings Date and Reports 2026 - marketbeat.com
MIRA Pharmaceuticals Edges Higher: Stock Gains 1.37% as Shares Hold Key Support LevelEnding Diagonal - careplusvn.com
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss of -$0.06 Per Share Highlights Cost DisciplineMargin Expansion Trends - careplusvn.com
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives 9.36% Stock GainRevenue Per Share - dars.gov.et
Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com South Africa
MIRA's obesity candidate shows rapid absorption in 7-day dog study - stocktitan.net
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 - Asianet Newsable
MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1 - TipRanks
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
Market Movers | Winners: AEMD, HYFM, FUSE | Losers: GYGY, CALC, MIRA - Trefis
12 Health Care Stocks Moving In Monday's After-Market SessionEnsysce Biosciences (NASDAQ:ENSC), TransC - Benzinga
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue StageCash Flow Report - dars.gov.et
MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA - TradingView
Tangible book value per share of MIRA Pharmaceuticals, Inc. – MUN:K6S - TradingView
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice - TipRanks
Mira advances MIRA-55 and SKNY-1 - bioworld.com
Mira Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies - GlobeNewswire
MIRA Q3 2025 Earnings: EPS Beat on Narrower Loss Highlights Cost DisciplineFull Year Guidance - dars.gov.et
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Stock DeclineEarnings Call Highlights - dars.gov.et
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Q3 2025 Earnings: EPS Surprise of 26.47% on Narrowed Loss Despite No RevenueEarnings Miss Alert - vinanet.vn
MIRA|Mira Pharmaceuticals Inc|Price:0.764|Chg%:-0.025 - TradingKey
Mira Pharmaceuticals Inc (MIRA) Income Statement - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – DUS:K6S - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:+0.000 - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
MIRA Q3 2025 Earnings: Narrower-than-expected Loss Amid Pre-Revenue PhaseShare Repurchase Impact - careplusvn.com
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):